{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:22:33Z","timestamp":1744777353089,"version":"3.40.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants challenges the treatment of immunocompromised patients against coronavirus disease 2019 (COVID-19). High-titer COVID-19 convalescent plasma (CCP) remains one of the few available therapeutics for these patients. We have revisited the selection of CCP samples and evaluated their efficacy against the Omicron XBB.1.5 variant, the dominant strain in 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A surrogate enzyme-linked immunoassay was reviewed to select CCP samples that ensure a protective level of neutralizing antibodies as the main correlate of protection. Antibody titers were analyzed in 500 serum samples from a population-based serosurvey at Mount Sinai Hospital in early 2023, and the results were validated with CCP samples (collected in 2020\u20132023) using an immunosuppressed mouse model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Using logistic regression modeling, we have redefined high-titer CCP against the new variant in the postpandemic era, where over 97% of the population has natural or vaccine-induced antibodies against earlier SARS-CoV-2 strains. Treatment of immunocompromised mice with two doses (100 \u03bcL\/dose) of CCP plasma via intraperitoneal injection reduced lung viral titers by 46-fold 3 days post-XBB.1.5 infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings will guide future efforts in selecting high-titer CCP for emerging SARS-CoV-2 variants.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae645","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:56:27Z","timestamp":1735898187000},"page":"e723-e733","source":"Crossref","is-referenced-by-count":0,"title":["A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern"],"prefix":"10.1093","volume":"231","author":[{"given":"Victoria","family":"Dolange","sequence":"first","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-6597","authenticated-orcid":false,"given":"Stefan","family":"Slamanig","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"},{"name":"Swammerdam Institute for Life Sciences, University of Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2024-109X","authenticated-orcid":false,"given":"Adam","family":"Abdeljawad","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsoi Ying","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Lemus","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"},{"name":"Center for Vaccine Research and Pandemic Preparedness"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Carre\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"},{"name":"Center for Vaccine Research and Pandemic Preparedness"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anass","family":"Abbad","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"},{"name":"Center for Vaccine Research and Pandemic Preparedness"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"},{"name":"Center for Vaccine Research and Pandemic Preparedness"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"},{"name":"Center for Vaccine Research and Pandemic Preparedness"},{"name":"Department of Pathology, Molecular and Cell-Based Medicine"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaiprasath","family":"Sachithanandham","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University , Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-1761","authenticated-orcid":false,"given":"Andrew","family":"Pekosz","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University , Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0319-0578","authenticated-orcid":false,"given":"David","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University , Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"},{"name":"Center for Vaccine Research and Pandemic Preparedness"},{"name":"Department of Pathology, Molecular and Cell-Based Medicine"},{"name":"Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-5047","authenticated-orcid":false,"given":"Weina","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-5505","authenticated-orcid":false,"given":"Irene","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"2025041514234405400_jiae645-B1","first-page":"2322","article-title":"The role of convalescent plasma in COVID-19: a conclusive post-pandemic review","volume":"13","author":"Franchini","year":"2023","journal-title":"Life (Basel)"},{"key":"2025041514234405400_jiae645-B2","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group.","year":"2021","journal-title":"Lancet"},{"key":"2025041514234405400_jiae645-B3","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for Covid-19 with convalescent plasma","volume":"386","author":"Sullivan","year":"2022","journal-title":"N Engl J Med"},{"key":"2025041514234405400_jiae645-B4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/v15030765","article-title":"Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis on randomized controlled trials","volume":"15","author":"Filippatos","year":"2023","journal-title":"Viruses"},{"author":"National Institutes of Health","key":"2025041514234405400_jiae645-B5"},{"key":"2025041514234405400_jiae645-B6","doi-asserted-by":"crossref","first-page":"e00179-22","DOI":"10.1128\/msphere.00179-22","article-title":"PARIS and SPARTA: finding the Achilles\u2019 heel of SARS-CoV-2","volume":"7","author":"Simon","year":"2022","journal-title":"mSphere"},{"key":"2025041514234405400_jiae645-B7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-020-2912-6","article-title":"Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City","volume":"590","author":"Stadlbauer","year":"2021","journal-title":"Nature"},{"key":"2025041514234405400_jiae645-B8","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1002\/cpmc.100","article-title":"SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup","volume":"57","author":"Stadlbauer","year":"2020","journal-title":"Curr Protoc Microbiol"},{"key":"2025041514234405400_jiae645-B9","doi-asserted-by":"crossref","first-page":"105185","DOI":"10.1016\/j.ebiom.2024.105185","article-title":"Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in mice","volume":"105","author":"Slamanig","year":"2023","journal-title":"eBioMedicine"},{"key":"2025041514234405400_jiae645-B10","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1172\/JCI142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J Clin Invest"},{"key":"2025041514234405400_jiae645-B11","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/trf.17449","article-title":"SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019\u20132022","volume":"63","author":"Bloch","year":"2023","journal-title":"Transfusion (Paris)"},{"key":"2025041514234405400_jiae645-B12","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1093\/cid\/ciaa1616","article-title":"Repeated coronavirus disease 2019 molecular testing: correlation of severe acute respiratory syndrome coronavirus 2 culture with molecular assays and cycle thresholds","volume":"73","author":"Gniazdowski","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025041514234405400_jiae645-B13","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/cid\/ciad066","article-title":"Guidance on the use of convalescent plasma to treat immunocompromised patients with coronavirus disease 2019","volume":"76","author":"Bloch","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025041514234405400_jiae645-B14","doi-asserted-by":"crossref","first-page":"199319","DOI":"10.1016\/j.virusres.2024.199319","article-title":"Divergent pathogenetic outcomes in BALB\/c mice following Omicron subvariant infection","volume":"341","author":"Powers","year":"2024","journal-title":"Virus Res"},{"key":"2025041514234405400_jiae645-B15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41586-023-06487-6","article-title":"Neutralization, effector function and immune imprinting of Omicron variants","volume":"621","author":"Addetia","year":"2023","journal-title":"Nature"},{"key":"2025041514234405400_jiae645-B16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"2025041514234405400_jiae645-B17","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1038\/s41467-022-33864-y","article-title":"Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources","volume":"13","author":"Sullivan","year":"2022","journal-title":"Nat Commun"},{"key":"2025041514234405400_jiae645-B18","doi-asserted-by":"crossref","first-page":"e02257-20","DOI":"10.1128\/JCM.02257-20","article-title":"Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers","volume":"59","author":"Patel","year":"2021","journal-title":"J Clin Microbiol"},{"article-title":"Convalescent plasma: EUA letter of authorization","year":"2021","author":"O'Shaughnessy","key":"2025041514234405400_jiae645-B19"},{"key":"2025041514234405400_jiae645-B20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol Rev"},{"key":"2025041514234405400_jiae645-B21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"article-title":"Clinical memorandum\u2014COVID-19 convalescent plasma","year":"2021","author":"Villa","key":"2025041514234405400_jiae645-B22"},{"key":"2025041514234405400_jiae645-B23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/cid\/ciad088","article-title":"Coronavirus disease 2019 convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from 5 randomized trials","volume":"76","author":"Levine","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025041514234405400_jiae645-B24","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/bloodadvances.2022007410","article-title":"Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern","volume":"6","author":"Li","year":"2022","journal-title":"Blood Adv"},{"key":"2025041514234405400_jiae645-B25","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/vaccines11111644","article-title":"Clinical utility of SARS-CoV-2 serological testing and defining a correlate of protection","volume":"11","author":"Sobhani","year":"2023","journal-title":"Vaccines"},{"key":"2025041514234405400_jiae645-B26","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"key":"2025041514234405400_jiae645-B27","doi-asserted-by":"crossref","first-page":"e0075822","DOI":"10.1128\/jvi.00758-22","article-title":"A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection","volume":"96","author":"Abdelnabi","year":"2022","journal-title":"J Virol"},{"key":"2025041514234405400_jiae645-B28","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-023-42717-1","article-title":"Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time","volume":"14","author":"Kenny","year":"2023","journal-title":"Nat Commun"},{"key":"2025041514234405400_jiae645-B29","doi-asserted-by":"crossref","first-page":"e0328623","DOI":"10.1128\/spectrum.03286-23","article-title":"COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial","volume":"12","author":"Habtehyimer","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2025041514234405400_jiae645-B30","doi-asserted-by":"crossref","first-page":"114922","DOI":"10.1016\/j.celrep.2024.114922","article-title":"Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination","volume":"43","author":"Clark","year":"2024","journal-title":"Cell Rep"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae645\/61322175\/jiae645.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae645\/61322175\/jiae645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae645\/61322175\/jiae645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T14:52:46Z","timestamp":1744728766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/4\/e723\/7941845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae645","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2025,4,15]]},"published":{"date-parts":[[2025,1,3]]}}}